Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

SAGE Trial for Refractory Status Epilepticus

  • Broadcast in Health
Epilepsy Talk Radio

Epilepsy Talk Radio


Follow This Show

If you liked this show, you should follow Epilepsy Talk Radio.

Call in to speak with the host

(347) 215-9676


In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Steve Kanes, MD, PhD, Chief Medical Officer at SAGE Therapeutics about the SAGE 547 Trial in Status Epilepticus.

SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE). SAGE-547 demonstrated robust findings in preclinical models of SE, including significantly increased efficacy over current standard-of-care benzodiazepine treatment, and compelling early human experience data.

After the interview, you can learn more about refractory epilepsy at: http://www.epilepsy.com/learn/refractory-epilepsy.